Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12225330rdf:typepubmed:Citationlld:pubmed
pubmed-article:12225330lifeskim:mentionsumls-concept:C0521026lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C0035525lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C0524910lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C0449297lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:12225330lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:12225330pubmed:issue5lld:pubmed
pubmed-article:12225330pubmed:dateCreated2002-9-12lld:pubmed
pubmed-article:12225330pubmed:abstractTextHigh-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic hepatitis C were randomised to receive, after 4 weeks of 10 mU daily of alpha-interferon (induction), 3 mU daily for 22 weeks and 3 mU thrice weekly for 26 weeks of either interferon alone (monotherapy) or interferon plus 1000-1200 mg daily of ribavirin (combination therapy). At the end of the induction phase, 23 (56%) subjects had cleared HCV-RNA. During therapy, breakthrough was observed in four patients on monotherapy, but never in patients on combination therapy. The rate of clearance of HCV-RNA was different between monotherapy and combination therapy at the end of treatment (40% vs. 76.1%, P=0.02) and at the end of follow-up (5% vs. 57.1%, P=0.001). Twelve of the 23 patients who cleared HCV-RNA during induction, but only one of the 18 still HCV-RNA-positive after 4 weeks of therapy, had a sustained response (52.2% vs. 5.6%, P=0.001). Clearance of HCV-RNA at 1 week had a high positive predictive value for sustained response in combination therapy (PPV=0.75), but not in monotherapy (PPV=0.33). Induction with high daily doses of alpha-interferon obtains suppression of hepatitis C in more than half of patients, but ribavirin is needed to maintain a sustained response. The rate of sustained response is a function of the time to HCV-RNA clearance. In patients not responding to induction therapy addition of ribavirin does not obtain a sustained virological response.lld:pubmed
pubmed-article:12225330pubmed:languageenglld:pubmed
pubmed-article:12225330pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12225330pubmed:citationSubsetIMlld:pubmed
pubmed-article:12225330pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12225330pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12225330pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12225330pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12225330pubmed:statusMEDLINElld:pubmed
pubmed-article:12225330pubmed:monthSeplld:pubmed
pubmed-article:12225330pubmed:issn1352-0504lld:pubmed
pubmed-article:12225330pubmed:authorpubmed-author:CappelliGGlld:pubmed
pubmed-article:12225330pubmed:authorpubmed-author:AlmasioPPlld:pubmed
pubmed-article:12225330pubmed:authorpubmed-author:ParisiPPlld:pubmed
pubmed-article:12225330pubmed:authorpubmed-author:FerrariBBlld:pubmed
pubmed-article:12225330pubmed:authorpubmed-author:Di StefanoRRlld:pubmed
pubmed-article:12225330pubmed:authorpubmed-author:Di MarcoVVlld:pubmed
pubmed-article:12225330pubmed:authorpubmed-author:VaccaroAAlld:pubmed
pubmed-article:12225330pubmed:authorpubmed-author:CraxìAntonioAlld:pubmed
pubmed-article:12225330pubmed:authorpubmed-author:CinoNNlld:pubmed
pubmed-article:12225330pubmed:issnTypePrintlld:pubmed
pubmed-article:12225330pubmed:volume9lld:pubmed
pubmed-article:12225330pubmed:ownerNLMlld:pubmed
pubmed-article:12225330pubmed:authorsCompleteYlld:pubmed
pubmed-article:12225330pubmed:pagination354-9lld:pubmed
pubmed-article:12225330pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:meshHeadingpubmed-meshheading:12225330...lld:pubmed
pubmed-article:12225330pubmed:year2002lld:pubmed
pubmed-article:12225330pubmed:articleTitleEarly viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.lld:pubmed
pubmed-article:12225330pubmed:affiliationCattedra di Gastroenterologia, Clinica Medica, University of Palermo, Palermo, Italy. vito.dimarco@tin.itlld:pubmed
pubmed-article:12225330pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12225330pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12225330pubmed:publicationTypeRandomized Controlled Triallld:pubmed